Opus Genetics (IRD) Net Cash Flow (2010 - 2026)

Opus Genetics (IRD) has 17 years of Net Cash Flow data on file, last reported at $14.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 29.61% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $18.2 million, a 438.37% increase from a year earlier, with the FY2025 full-year figure at $14.8 million, up 173.19% from the prior year.
• Net Cash Flow for Q1 2026 stood at $14.9 million, up from $14.3 million in the prior quarter.
• Over the last five years, Net Cash Flow for IRD reached as high as $28.8 million in Q4 2022 and fell as low as -$9.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of -$2.2 million in 2022.
• Across the five-year window, Net Cash Flow jumped 1160.03% in 2022 and sank 681.6% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $28.8 million in 2022, then tumbled by 71.68% to $8.2 million in 2023, then slumped by 177.43% to -$6.3 million in 2024, then jumped by 326.21% to $14.3 million in 2025, then advanced by 4.15% to $14.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $14.9 million in Q1 2026, $14.3 million in Q4 2025, and -$1.6 million in Q3 2025.